MiRus is pleased to announce the launch of the US multi-center Early Feasibility Study of the Siegel™ 8-Fr aortic ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

MiRus announced that it launched a U.S. multi-center early feasibility study for its Siegel transcatheter heart valve (THV).

Both patients were discharged without complications the next day. The Siegel valve represents several firsts in TAVR: 8 French delivery sheath allowing less invasive procedures and broader patient ...

Aortic stenosis is a condition where the aortic valve narrows, obstructing blood flow from the heart to the aorta. As a ...

The COVID pandemic could be a cause, but perhaps not the only reason, for the changes from 2018 to 2022. Only time will tell.

Despite a solid Q4 earnings beat, Edwards Lifesciences' shares remain undervalued with a reduced P/E multiple of 33x. Read why EW stock is a Buy.

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut ... Any forward-looking statements are subject to risks and uncertainties such as those described in ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut� ...